A downtrend has been apparent in Blueprint Medicines (BPMC) lately. While the stock has lost 8.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future ...

Blueprint Medicines Corporation (BPMC) reported second-quarter 2024 adjusted loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.28. The company had reported a loss of $2.19 per share in the year-ago quarter. Quarterly revenues of $138.2 million surpassed the Zacks Consensus Estimate of $105 million. Total revenues jumped almost 140% year over year. Despite the better-than-expected results, shares of Blueprint Medicines were down 7.4% on Aug 1 following the earnings announ ...

Financial Data and Key Metrics - Total revenues for Q2 2024 were $138.2 million, including $114.1 million in net product revenues from AYVAKIT and $24 million in collaboration, license, and other revenues [22] - AYVAKIT achieved $114.1 million in net product revenue, with $101.5 million in the US and $12.7 million ex-US, representing a year-over-year growth of more than 185% [9] - The company raised its AYVAKIT product revenue guidance to $435 million to $450 million for 2024, reflecting strong performance in the first half of the year [22] Business Line Performance - AYVAKIT's growth in the US was driven by new patient starts, low discontinuation rates, high compliance, and favorable commercial versus free goods mix [9] - The international team had an exceptional quarter, with the ISM launch underway in Germany and plans to expand to additional countries in 2025 [12] - The company expects continued strength in its international business, which is seen as an important contributor to future growth [12] Market Performance - The US market saw strong growth in AYVAKIT revenue, driven by expanding prescriber base and low discontinuation rates [9] - In Germany, the ISM launch is progressing well, with growing prescriber bases in both academic and community settings [12] - The company anticipates further international expansion, particularly in Europe, where pricing and reimbursement negotiations are ongoing [58] Company Strategy and Industry Competition - The company is focused on building a franchise in mast cell disorders with AYVAKIT, elenestinib, and BLU-808, targeting a multibillion-dollar market opportunity [18] - BLU-808, a wild-type KIT inhibitor, has entered clinical trials, with initial data expected early next year, potentially impacting a range of mast cell diseases [7][19] - The company is also advancing its cell cycle inhibition strategy, with BLU-222 and targeted protein degradation platforms, aiming to address unmet medical needs in oncology [20] Management Commentary on Operating Environment and Future Outlook - Management expressed strong confidence in AYVAKIT's long-term revenue potential, citing its unique value proposition and positive reception among physicians, patients, and payers [5][6] - The company highlighted the importance of patient compliance and long-term therapy duration as key drivers of future revenue growth [10] - Management noted that the chronic burden of ISM is often underappreciated and emphasized the need to redefine treatment expectations for patients and providers [15] Other Important Information - The company has $868.5 million in cash on hand, providing financial flexibility to invest in innovation and long-term growth [24] - Research and development expenses and SG&A expenses are expected to remain relatively flat for the remainder of the year [24] - The company is focused on driving long-term shareholder value through the successful launch of AYVAKIT and disciplined expense management [24] Q&A Session Summary Question: Quarterly dynamics and impact of Part D redesign on AYVAKIT launch [26] - Management noted seasonal dynamics in patient starts, with potential delays during vacation and holiday periods, but emphasized that the opportunity remains strong [28][29] - The proportion of free goods has stabilized at just under 20%, with no significant changes expected for the rest of the year [30] Question: Eligibility for AYVAKIT and long-term patient eligibility trends [33] - Providers are broadening their view of who is an appropriate patient for AYVAKIT, with a trend towards treating patients with fewer but impactful symptoms [34][35] - The company believes the prevalence of ISM may be underestimated, potentially leading to a larger patient population than initially thought [37] Question: Growth rate and potential for AYVAKIT to exceed $2 billion peak revenue [39] - Management reiterated confidence in AYVAKIT's peak revenue potential, citing strong year-over-year growth and expanding patient eligibility [41][43] - The company is monitoring factors such as broadening patient eligibility and increasing diagnosed patient numbers to assess potential for higher peak revenue [44] Question: Treatment duration and refill rates for AYVAKIT [47] - Patients on AYVAKIT are trending towards long-term therapy, with low discontinuation rates and high compliance, consistent with a multiyear duration of therapy [47][48] Question: Prescriber base expansion and strategy for AYVAKIT [50] - The prescriber base for AYVAKIT is expanding beyond the initial target of 400 physicians, with increasing adoption across hematologists, oncologists, and allergists [50][51] Question: Discontinuation rates and financial sustainability of BLU-808 development [53] - Discontinuation rates for AYVAKIT are very low, with patients staying on therapy for long durations [54] - The development of BLU-808 is factored into the company's financial guidance, with initial data expected to be a significant inflection point [56][57] Question: International expansion plans for AYVAKIT [58] - The company is focused on expanding AYVAKIT's presence in international markets, with ISM launches expected in additional countries in 2025 [58] Question: Spectrum of disease severity and patient eligibility for AYVAKIT [60] - The company is seeing a broadening of patient eligibility for AYVAKIT, with providers increasingly treating patients with less severe symptoms [63][64] Question: Biomarkers and metrics for BLU-808 healthy volunteer study [62] - The healthy volunteer study for BLU-808 will focus on safety, pharmacokinetics, and pharmacodynamics, with data expected to inform the breadth of its application [66] Question: Net pricing trends and revenue growth drivers for AYVAKIT [69] - There have been no quarter-over-quarter net pricing increases for AYVAKIT, with revenue growth driven by volume rather than price [70] Question: Prescriber trends in academic vs. community centers [72] - Prescribing trends for AYVAKIT are strong across both academic and community settings, with deepening adoption among experienced prescribers [73] Question: Differentiation of elenestinib and timeline for pivotal study [75] - Elenestinib, a next-generation KIT D816V inhibitor, is being developed with a focus on clinical differentiation in ISM, with Part 2 of the HARBOR study expected to begin by year-end [76] Question: Free drug dynamics and dose escalation trends for AYVAKIT [78] - The proportion of free goods has stabilized, with no significant changes expected for the rest of the year [81] - The majority of ISM patients start at 25 mg, with limited utilization of higher doses [82] Question: Business development strategy and challenges in HARBOR study enrollment [85] - The company is open to both inbound and outbound business development opportunities, with a focus on advancing its mast cell disorder franchise [86][87] - No major challenges are expected in enrolling patients for the HARBOR study, with international sites planned to support recruitment [89]

Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of Regi ...

Second Quarter 2024 Financial Results AUG 1, 2024 Agenda INTRODUCTION AYVAKIT PERFORMANCE Kate Haviland Chief Executive Officer Philina Lee, PhD Chief Commercial Officer CORPORATE PROGRESS Christy Rossi Chief Operating Officer | --- | --- | --- | |-------|-------------------------|-------| | | | | | | | | | | | | | | Q2 2024 FINANCIAL | | | | PERFORMANCE | | | | | | | | Mike Landsittel | | | | Chief Financial Officer | | Not for promotional use 2 Forward-looking statements 3 This presentation contains forwa ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.28. This compares to loss of $2.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this cancer drug developer would post a loss of $1.64 per share when it actually produced a loss of $1.32, delivering a surprise of 19.51%. Over the last four quarters, the ...

Exhibit 99.1 Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance -- Achieved $114.1 million in AYVAKIT net product revenues in the second quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $435 million to $450 million for 2024 -- -- Initiated Phase 1 healthy volunteer trial of wild-type KIT inhibitor BLU-808 -- CAMBRIDGE, Mass., August 1, 2024 – Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial resu ...

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). Expected Results of an Industry Player While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicappin ...

To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 299779. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call. Blueprint Medi ...

Core Insights - Blueprint Medicines Corporation is advancing the understanding and treatment of systemic mastocytosis (SM) through multiple upcoming datasets presented at key conferences, emphasizing the real-world burden of the disease and the clinical outcomes of AYVAKIT/AYVAKYT (avapritinib) [1][2][5] Group 1: Clinical Efficacy and Safety of AYVAKIT - AYVAKIT demonstrated durable efficacy and a favorable safety profile in patients with indolent systemic mastocytosis (ISM) over a median follow-up of more than two years, with safety data consistent for approximately 10% of patients who escalated to a 50 mg daily dose [1][2] - The median overall survival (OS) for AYVAKIT in advanced SM has not been reached, with a historical median OS ranging from less than six months to about 3.5 years, and an overall response rate of 73% [3][4] - AYVAKIT showed sustained improvements in total symptom scores and quality of life, with the most common treatment-related adverse event being edema, primarily Grade 1, and a low discontinuation rate of 3% due to treatment-related adverse events [2][4] Group 2: Patient Perspectives and Disease Burden - The PRISM Survey highlighted the significant burden of systemic mastocytosis on patients' quality of life, with many reporting debilitating symptoms and impaired physical and mental health functioning [5][6] - Healthcare providers acknowledged the impact of SM, with 65% indicating it affected patients' lives "quite a bit" or "a great deal," and 58% noting that patients lost employment opportunities due to the disease [6] Group 3: Upcoming Presentations and Research - Data presentations will be made available at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 and the European Hematology Association 2024 (EHA24) Hybrid Congress, covering various aspects of AYVAKIT's safety, efficacy, and the burden of SM [7][8]